<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03305783</url>
  </required_header>
  <id_info>
    <org_study_id>H-15016324</org_study_id>
    <nct_id>NCT03305783</nct_id>
  </id_info>
  <brief_title>The Influence of Cholecystectomy on Secretion of Incretin Hormones</brief_title>
  <official_title>The Influence of Cholecystectomy on Secretion of Incretin Hormones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of cholecystectomy on postprandial plasma GLP-1 responses (primary endpoint) and
      glucose metabolism will be evaluated in 30 patients planned to undergo elective laparoscopic
      cholecystectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, parallel-group study in 30 patients with gallstone disease and 10
      healthy control subjects. In patients undergoing cholecystectomy a 4h-meal test (liquid mixed
      meal) will be conducted at baseline (1-2 weeks before surgery) and again within 4 weeks after
      the cholecystectomy. Healthy subjects will be submitted to a single 4h-meal test.

      Secondary endpoints include changes in plasma glucose, insulin, glucagon, GIP, PYY, gastrin,
      CCK, fibroblast growth factor 19 (FGF-19) and bile acids. Furthermore, secondary endpoints
      include changes in gastric emptying (evaluated by the paracetamol method).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial GLP-1 response</measure>
    <time_frame>240 min</time_frame>
    <description>Gut derived hormone secretion after a 4 h meal test measured in pmol/liter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma glucose</measure>
    <time_frame>240 min</time_frame>
    <description>measured in mmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gastric emptying</measure>
    <time_frame>240 min</time_frame>
    <description>evaluated by the paracetamol method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting metabolic rate</measure>
    <time_frame>240 min</time_frame>
    <description>evaluated by calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin</measure>
    <time_frame>240 min</time_frame>
    <description>measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon</measure>
    <time_frame>240 min</time_frame>
    <description>measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PYY</measure>
    <time_frame>240 min</time_frame>
    <description>peptide YY, measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIP</measure>
    <time_frame>240 min</time_frame>
    <description>measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCK</measure>
    <time_frame>240 min</time_frame>
    <description>Cholecystokinin, measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FGF-19</measure>
    <time_frame>240 min</time_frame>
    <description>Fibroblast growth factor 19, measured in ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrin</measure>
    <time_frame>240 min</time_frame>
    <description>measured in pmol/liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bile acids</measure>
    <time_frame>240 min</time_frame>
    <description>measured in nmol/ml</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glucose Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Patients having cholecystectomy</arm_group_label>
    <description>Healthy, normal weight patients (BMI&lt;27) undergoing elective cholecystectomy will have a meal test performed before and after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy matched controls will have one meal test performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cholecystectomy</intervention_name>
    <description>elective cholecystectomy performed due to gallstones, cholecystitis or other non-malignant conditions and therefore done regardless of the protocol of this study.</description>
    <arm_group_label>Patients having cholecystectomy</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      biopsies from the gallbladder and ductus cysticus after cholecystectomy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A healthy, normal weight population undergoing elective surgery because of gall stone
        disease.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  caucasians above 18 years of age, having an elective cholecystectomy performed because
             of gallstone disease.

          -  normal fasting plasma glucose and HbA1c

          -  normal hgb

          -  Normal gallbladder ejection fraction

        Exclusion Criteria:

          -  liver disease

          -  kidney disease

          -  diabetes

          -  ongoing infection

          -  abdominal pain not related to gall stones

          -  BMI &lt;18,5 kg/m2 eller BMI &gt;27 kg/m2

          -  prior abdominal surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K Knop, MD. Proff.</last_name>
    <role>Study Director</role>
    <affiliation>Center for Diabetes research, Gentofte hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christina C. Nexoe-Larsen, MD</last_name>
    <phone>004528708077</phone>
    <email>christina.charlotte.nexoee-larsen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Filip K. knop, MD. Proff.</last_name>
    <email>filip.kragh.knop01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical metabolic physiology, Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <state>Hellerup</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina C Nex√∏e-Larsen, MD, Ph.D. student</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Christina Charlotte Nexoe-Larsen</investigator_full_name>
    <investigator_title>MD, Ph.D. student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

